HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE research hub

A Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

This study is testing a new medicine, BDC-1001, for advanced breast cancer that has spread. It's for people whose cancer has a specific marker called HER2. We want to see how well BDC-1001 works alone and with another drug, pertuzumab.